Figure 1From: Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitmentModel of myofibroblast origin in skin lesions of scleroderma patients. Transforming growth factor β, endothelin-1 and CCN2 can enhance differentiation of resident fibroblasts to myofibroblasts; platelet derived growth factor promotes pericyte recruitment.Back to article page